Crescent Biopharma develops cancer treatments, including antibody and antibody drug conjugate candidates still in clinical trials. It last closed at $13.00 on Nov 20, up 0.70% on the day. The next earnings report for CBIO is expected around Thu, Feb 25, 2027. Over its last 8 reports the stock moved an average of 3.0% the session after earnings. Over the last 12 months CBIO insiders bought $30.6M of stock on the open market and sold $1.5M, according to SEC Form 4 filings.
AI Auto Pilots
Is CBIO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CBIO.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on CBIOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
CBIO · as of the Nov 20 close · updated each morning
Downtrend
The stock is 3% below its 20 day and 8% below its 50 day average. It is 23% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 45). The nearest support is the Pivot at $12.94, and the nearest resistance the Pivot R1 at $13.36.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 8.5%/day
Key levels
$27.4152 week high+110.8%
$16.04200 day average+23.4%
$15.52100 day average+19.4%
$14.1050 day average+8.5%
$13.81Swing high (Oct 21)+6.2%
$13.4520 day average+3.5%
$13.36Pivot R1+2.8%
$13.00Last close
$12.94Pivot−0.5%
$12.68Swing low (Nov 2)−2.5%
$12.59Pivot S1−3.2%
$8.7252 week low−32.9%
Indicators
RSI (14)
45.04
Middle of its range
Neutral
MACD
-0.24
Below its signal line
Bearish
Stochastic
17.4
Near the bottom of its range
Oversold
ADX (14)
11.3
No clear trend
Williams %R
-74.5
Oversold below −80, overbought above −20
Neutral
CCI (20)
-78.0
Oversold below −100, overbought above 100
Neutral
Rate of change
−4.0%
Change over 10 sessions
Bearish
ATR (14)
$1.10
Typical daily range, 8.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 21.1%/day
Key levels
$27.4152 week high+110.8%
$16.04200 day average+23.4%
$15.52100 day average+19.4%
$14.1050 day average+8.5%
$13.81Swing high (Oct 21)+6.2%
$13.4520 day average+3.5%
$13.36Pivot R1+2.8%
$13.00Last close
$12.94Pivot−0.5%
$12.68Swing low (Nov 2)−2.5%
$12.59Pivot S1−3.2%
$8.7252 week low−32.9%
Indicators
RSI (14)
43.18
Middle of its range
Neutral
MACD
-0.87
Below its signal line
Bearish
Stochastic
16.9
Near the bottom of its range
Oversold
ADX (14)
14.0
No clear trend
Williams %R
-88.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-94.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−33.0%
Change over 10 sessions
Bearish
ATR (14)
$2.74
Typical daily range, 21.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Below
What happened before, for CBIO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow CBIO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for CBIOHow many large options trades hit CBIO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in CBIO in the last 90 days.
From SEC Form 4 filings by CBIO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CBIO is in one of them and how their past CBIO trades turned out.
Crescent Biopharma is a biotechnology company based in Waltham, Massachusetts, that develops treatments for cancer. Its lead candidate, CR-001, is an antibody designed to bind two proteins, PD-1 and VEGF, that affect how tumors grow and how the immune system responds. The company is also developing antibody drug conjugates, which are designed to deliver a toxin directly to cancer cells. Its candidates are still in clinical trials and are not yet approved for sale.